← Back to Search

Vitamin

Nicotinamide Riboside for High Blood Pressure

Phase 2

Recruiting

Research Sponsored by Douglas Seals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial will help determine if nicotinamide riboside is a safe and effective way to lower blood pressure and reduce the risk of cardiovascular disease.

Who is the study for?

This trial is for middle-aged and older adults who have slightly elevated blood pressure (120-159 mmHg) and are generally healthy. Participants should not be on blood pressure medication, must have a stable weight, BMI under 40 kg/m2, normal cholesterol and glucose levels, no chronic diseases like diabetes or kidney disease, non-smokers, and not heavy drinkers.Check my eligibility

What is being tested?

The study tests if Nicotinamide riboside can lower high systolic blood pressure and make arteries less stiff in people as they age. It's compared to a placebo over three months in a double-blind setup where neither the researchers nor participants know who gets the real supplement.See study design

What are the potential side effects?

Potential side effects of Nicotinamide riboside may include digestive issues such as nausea or indigestion since it affects metabolism. However, specific side effects will be monitored during the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Systolic blood pressure

Secondary outcome measures

Ambulatory blood pressure

Arterial stiffness

Other outcome measures

Adherence to the intervention (percentage of prescribed pills consumed)

Inflammation

NAD+ and related metabolite blood levels

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Nicotinamide ribosideExperimental Treatment1 Intervention

Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.

Group II: PlaceboPlacebo Group1 Intervention

Subjects will take placebo pills twice a day for 3 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nicotinamide riboside

2021

Completed Phase 3

~400

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Douglas SealsLead Sponsor

2 Previous Clinical Trials

89 Total Patients Enrolled

Media Library

Nicotinamide Riboside (Vitamin) Clinical Trial Eligibility Overview. Trial Name: NCT03821623 — Phase 2

High Blood Pressure Research Study Groups: Placebo, Nicotinamide riboside

High Blood Pressure Clinical Trial 2023: Nicotinamide Riboside Highlights & Side Effects. Trial Name: NCT03821623 — Phase 2

Nicotinamide Riboside (Vitamin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03821623 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the criteria for inclusion in this clinical trial?

"This medical trial is recruiting a total of 118 hypertensive individuals aged between 50 and 79."

Answered by AI

Does this research protocol exclude persons over the age of fifty?

"This particular medical trial requires that participants' ages range from 50 to 79 years old. Conversely, there are 55 trials for minors and 906 studies for those over 65."

Answered by AI

How many participants are currently included in the experiment?

"Affirmative. According to information found on clinicaltrials.gov, the medical trial is actively recruiting participants and was initially posted in May 10th 2019. An update was made as recent as February 14th 2022 and 118 individuals are being sought from a single site."

Answered by AI

Could you describe any other investigations into the effects of Nicotinamide riboside?

"Presently, 15 Nicotinamide riboside clinical trials are ongoing with 1 study in its final phase. 19 medical centres across the US are participating in these experiments; most of which are located near Iowa City, Iowa."

Answered by AI

Is enrollment open for this clinical experiment currently?

"According to clinicaltrials.gov, this medical investigation is actively recruiting participants. Inception of the trial was May 10th 2019 and it's been recently updated on February 14th 2022."

Answered by AI

What potential risks have been associated with Nicotinamide riboside intake?

"There is limited proof that nicotinamide riboside has a positive effect on patient health, so it was given an assessment of 2 on our team's internal scale."

Answered by AI

Recent research and studies

Nature CommunicationsJournal

Chronic Nicotinamide Riboside Supplementation Is Well-tolerated and Elevates NAD+ in Healthy Middle-aged and Older Adults

Martens, Christopher R., Blair A. Denman, Melissa R. Mazzo, Michael L. Armstrong, Nichole Reisdorph, Matthew B. McQueen, Michel Chonchol, and Douglas R. Seals. 2018. “Chronic Nicotinamide Riboside Supplementation Is Well-tolerated and Elevates NAD+ in Healthy Middle-aged and Older Adults”. Nature Communications. Springer Science and Business Media LLC. doi:10.1038/s41467-018-03421-7.

Frontiers in Cardiovascular MedicineJournal

Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults

Freeberg, Kaitlin A., Daniel H. Craighead, Christopher R. Martens, Zhiying You, Michel Chonchol, and Douglas R. Seals. 2022. “Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults”. Frontiers in Cardiovascular Medicine. Frontiers Media SA. doi:10.3389/fcvm.2022.881703.

clinicaltrials.govStudy

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

Douglas Seals 2019. "Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03821623.

All > Blood Pressure